FDA Compliance Experts Advise Against Treating Minor Changes As ‘Planned Deviations’
It’s all about change control and risk management, FDA compliance experts tell rapt audience at PDA/FDA conference when confronted with the common practice of planning deviations so that production won’t falter.
You may also be interested in...
Quality and the measure of a firm: Toyobo’s particulates and resins, Galenicko’s sanitation, Breckenridge’s product chemistry and Fujifilm’s cross-contamination risk.
High-level board will bring together information from across FDA drug center and work to increase supply chain transparency, says CDER’s Jacqueline Corrigan-Curay.
XGBoost model sees site complexity contributes to quality risk, but misses device-related issues, says third FDA pharmaceutical quality report.